RECK gene polymorphisms influence NSCLC susceptibility, but not the chemotherapy response status in Chinese cohort

Bioinformatics and meta-analysis of the clinical significance of RECK expression and its genetic polymorphisms in cancer

RECK plays an important role in the development of cancer. The current study focuses on exploring the clinical significance of RECK expression in cancer by mining public data and also evaluating the relationship between genetic polymorphisms of the RECK gene and cancer risk through meta-analysis. The results showed that RECK expression was not only associated with survival prognosis and immune infiltration in many types of cancers, but also with multiple drug sensitivity in pan-cancer. In addition, the RECK rs10814325 polymorphism was also associated with cancer risk under the homozygote comparison model (CC vs. TT: OR = 1.64, 95%CI = 1.03-2.61, p = 0.04) and the recessive genetic model [CC vs. (CT + TT): OR = 1.55, 95%CI = 1.27-1.89, p < 0.01]. In conclusion, these findings suggest that RECK expression levels may serve as a valuable indicator for assessing cancer prognosis in some cancers as well as drug sensitivity in pan-cancer, and its rs10814325 polymorphism may be used to assess cancer risk.

RASSF1A, RECK genotypes and haplotypes in Egyptian population with Hepatocellular carcinoma

BACKGROUND AND OBJECTIVES

The development of HCC is multifactorial, resulting from the interaction of environmental factors (possibly hepatitis viruses) and host factors (genetic factors). So identification of risk factors that contribute to HCC and thus early diagnosis and therapy is necessary. This study aimed to investigate the role of tumor suppressor genes RASSF1A Ala133Ser and RECK rs11788747polymorphisms and their haplotypes in HCC.

SUBJECTS AND METHODS

104 cases of HCC and 100 healthy controls were included in a case-control study. RASSF1A and RECK genotypes, allele and haplotypes were detected by PCR-RFLP.

RESULTS

Risk of HCC was significantly associated with carriers of A1a/Ser, Ser/Ser, Ser allele and A1a/Ser +GA haplotypes (OR=20.57, p<0.001, OR=7.26, p=0.05, OR=10.64, p<0.001, OR=12.52, p=0.005) respectively. More over RECK GG, G allele and haplotype A1a/A1a+GG were protective to HCC (OR=0.11, p<0.001, & OR=0.53, p=0.001 & OR=0.16, p=0.002) respectively. Also, it was found that RASSF1A gene polymorphism significantly associated with bad pathological features but no association with RECK gene polymorphism.

CONCLUSIONS

The RASSF1AAla133Ser polymorphism, RECK gene polymorphism and for the first time haplotype of both genes influence molecular carcinogenesis and clinic pathological features of HCC within the Egyptian population.

RECK Gene Polymorphism is Associated with Susceptibility and Prognosis of Wilms' Tumor in Chinese Children

Background

Wilms’ tumor (WT) is the most common malignant renal tumor in children. Previous studies suggested the reversion-inducing, cysteine-rich protein with Kazal motifs (RECK) down-regulation might have a role in numerous human cancers. The current study was done to investigate the associations of RECK single-nucleotide polymorphisms (SNPs) with the WT susceptibility in Chinese children.

Material/Methods

We analyzed 2 SNPs (rs10972727and rs11788747) in a total of 97 WT children and 194 healthy matched controls (1:2 ratio) by real-time PCR and PCR-RFLP genotyping analysis.

Results

We found that the G allele of rs11788747 in the RECK gene was significantly associated with WT in Chinese children (OR=0.7, 95% CI: 0.45–0.99; P=0.042); as with another SNP rs10972727, however, no statistically significant difference was detected. Further analysis showed there was also a statistically significant difference in genotype frequencies between terminal tumor stage (P=0.026) and metastatic groups (P=0.002).

Conclusions

The present data indicate that there is a significant association between mutant G of rs11788747 in RECK and WT risk. G carriers with advanced tumor stage or with metastasis might have an increased risk of WT.